Haemadin-Interrupta-1
Bivalent exosite-II thrombin inhibitor from the Malayan land leech Haemadipsa interrupta — Müller 2024 transcriptome identification + recombinant functional characterization.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Bivalent exosite-II thrombin inhibitor from the Malayan land leech Haemadipsa interrupta — Müller 2024 transcriptome identification + recombinant functional characterization.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
Haemadin-Interrupta-1's in vitro thrombin inhibition does NOT establish clinical efficacy. No FDA-approved derivative exists; H. interrupta is taxonomically distinct from the FDA-cleared K040187 medicinal leech species.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 5,400 Da
- Source species
- Haemadipsa interrupta
- Discovered
- 2024 · Müller C et al.
Biological Targets
- → thrombin exosite II
Key Citations
- Müller C et al. (2024), Parasitol Res · PMID 39570434
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.